The first patient has been dosed in a phase 3 clinical trial of Dextenza for the treatment of allergic conjunctivitis, Ocular Therapeutix announced in a press release.
The multicenter, randomized, double-masked, placebo-controlled trial will include 80 subjects and evaluate the safety and efficacy of Dextenza (dexamethasone ophthalmic insert 0.4 mg) compared with a placebo vehicle punctum plug. It will assess the effect of Dextenza on allergic reactions using a series of successive allergen challenges over 30 days, the release said.
“We believe Dextenza has the potential to replace the
Uncategorized